Vascular Disrupting Agents (vdas) - Cancer Science

Relevant Publications

Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules.

Issue Release: 2024

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.

Issue Release: 2024

Multi-parametric investigations on the effects of vascular disrupting agents based on a platform of chorioallantoic membrane of chick embryos.

Issue Release: 2024

Molecular Dynamics and Machine Learning reveal distinguishing mechanisms of Competitive Ligands to perturb α,β-Tubulin.

Issue Release: 2023

Synthesis and biological evaluation of structurally diverse 6-aryl-3-aroyl-indole analogues as inhibitors of tubulin polymerization.

Issue Release: 2023

Preparation and Characterization Evaluation of Poly(L-Glutamic Acid)--Methoxy Poly(Ethylene Glycol)/Combretastatin A4/BLZ945 Nanoparticles for Cervical Cancer Therapy.

Issue Release: 2023

Light-driven Self-recruitment of Biomimetic Semiconducting Polymer Nanoparticles for Precise Tumor Vascular Disruption.

Issue Release: 2023

Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.

Issue Release: 2022

Impact of Blood-Brain Barrier to Delivering a Vascular-Disrupting Agent: Predictive Role of Multiparametric MRI in Rodent Craniofacial Metastasis Models.

Issue Release: 2022

Development and characterization of a chick embryo chorioallantoic membrane (CAM) based platform for evaluation of vasoactive medications.

Issue Release: 2022

A self-activating nanoized vascular disrupting agent for selective anti-tumor therapy.

Issue Release: 2022

Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment.

Issue Release: 2022

Clinical Application of Tumor Vascular Disrupting Therapy: A Systematic Review and Meta-Analysis.

Issue Release: 2021

The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent-DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors.

Issue Release: 2021

Artificial tumor microenvironment regulated by first hemorrhage for enhanced tumor targeting and then occlusion for synergistic bioactivation of hypoxia-sensitive platesomes.

Issue Release: 2021

Utilisation of Chick Embryo Chorioallantoic Membrane as a Model Platform for Imaging-Navigated Biomedical Research.

Issue Release: 2021

Anti-vascular nano agents: a promising approach for cancer treatment.

Issue Release: 2020

Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation.

Issue Release: 2020

Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

Issue Release: 2020

Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular Disrupting Agent Administration.

Issue Release: 2020

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Vascular Disrupting Agents (vdas) - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics